NuCana plc - ADR

Name: NuCana plc - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: NuCana plc - ADR

Stock Card

$1.38

$-0.09 (-6.12%)

As on 01-Sep-2026 16:26EDT

Market cap

$7 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

0.2

Div. Yield

0 %

NuCana - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 1.36 High: 1.45

52 Week Range

Low: 1.21 High: 7.22

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.7 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

0.3
Debt to Equity

0
Book Value

$--
EPS

$-2.4
Face value

--
Shares outstanding

4,161,971

10 Years Aggregate

CFO

£-161.70 Mln

EBITDA

£-234.03 Mln

Net Profit

£-210.20 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
NuCana - ADR	-61.7	4.5	-40.8	-56.7	-96.4	-89.5	--
BSE Sensex	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
NuCana - ADR	-100.0	297.5	-55.2	-72.3	-47.0	-26.4	-57.9
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About NuCana - ADR

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs... into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom. Read more

Founder, CEO & Executive Director

Mr. Hugh Stephen Griffith
Founder, CEO & Executive Director

Mr. Hugh Stephen Griffith
Headquarters

Edinburgh
Website

https://www.nucana.com

FAQs for NuCana - ADR

What is the current share price of NuCana plc - ADR Today?

The share price of NuCana plc - ADR is $1.38 (NASDAQ) as of 01-Sep-2026 16:26 EDT. NuCana plc - ADR has given a return of -96.37% in the last 3 years.

What is the current PB & PE ratio of NuCana plc - ADR?

The P/E ratio of NuCana plc - ADR is 0.02 times as on 28-Aug-2026.
The P/B ratio of NuCana plc - ADR is 0.22 times as on 28-Aug-2026, a 96 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.